Pharmacogenomics Reporter GenomeWeb News Premium Content Existing subscribers login here. New to Pharmacogenomics Reporter? For a trial subscription click here.

FDA Updates Carbamazepine Label to Urge
Genetic Testing for Rare Skin Reactions

[December 19, 2007]

By Turna Ray

The FDA requested makers of a drug indicated for epilepsy, bipolar disorder, and neuropathic pain to add a black box warning recommending doctors to test patients of Asian ancestry for the HLA-B*1502 polymorphism due to the increased risk of Stevens Johnson Syndrome and toxic epidermal necrolysis. Specialty labs such as LabCorp and Quest have said they can accommodate such genetic testing.

Login | Subscribe